• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Certification, Purchasing and Quality Assurance

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Medical device QMS audit guidelines for product registration are open for comment

Medical device QMS audit guidelines for product registration are open for comment

medical device qms audit
Tuesday, 21 June 2022 / Published in Medical Device, News, NMPA Registration in China

Medical device QMS audit guidelines for product registration are open for comment

China’s NMPA has issued draft guidelines on medical device QMS audit for product registration. The draft Guideline for Inspection of Quality Management System for Medical Device Registration (Revision Draft for Comments) is open for comments by industry stakeholders until June 27, 2022.

This draft is a revision to the 2020 version.  

Scope of Application

This guideline applies to the on-site audit of the Quality Management System (QMS) for Class II and Class III medical device registration carried out by the regulatory authorities.

Key Points on the On-site Audit

  • Quality Management System principle
  • Institution & people
  • Plant, facilities and equipment
  • File management
  • Design and development
  • Procurement
  • Production
  • Quality control
  • Commissioned production
  • Product authenticity

Noteworthy Points

Research and development

For the situation of entrusted research and development (R&D), the applicant should have quality management measures for related activities. The applicant should sign a commissioned R&D agreement with the entrusted R&D institution, clearly stipulating the responsibilities of all parties, the content of R&D and related technical matters. The applicant should be responsible for the process and results of the commissioned R&D, as well as ensuring the reliability of data in the commissioned R&D process. The entrusted institution should comply with the requirements of the agreement to ensure that the R&D process is standardized, and that the data is true, accurate and traceable.

It is worth highlighting that the Guideline once promulgated will, for the first time, provide legal basis for commissioned R&D.

Commissioned production

Where there is a situation of entrustment in the process of R&D or production, the applicant should clarify the departments and personnel responsible for guiding and supervising the quality management system of the entrusted enterprises. Applicants should:

  • trace and monitor the whole process of R&D, production, storage and transportation as well as adverse event monitoring,
  • maintain the continuous improvement of the quality management system,
  • and implement the supervision of the entrusted enterprises.

Checklist of medical device QMS inspection items

A list of inspection items can be found in the appendix to the Guidelines. There are a total of 73 inspection items, of which 32 are key items and 41 are general items. The on-site audit team will make conclusions of “conformed”, “non-conformed” or “non-applicable” to each items separately.

How to submit comments on the medical device QMS audit for product registration guidelines

The deadline for comments is June 27, 2022. Cisema customers may submit their comments to their respective regulatory affairs project manager otherwise comments may be sent directly to mdgmp@cfdi.org.cn, and the subject of the email should be marked as “Comments on the Revision Draft of the Guideline for Inspection of Quality Management System for Medical Device Registration “.

By Grace and Victoria. If you require assistance in establishing a China conform medical device QMS or our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods, contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

CSAR China cosmetics infringements
CSAR China cosmetics infringements lead to suspension of lavender essential oil production
Sampling Inspection
NMPA Initiates Working Plan for Medical Device Sampling Inspection
NMPA report on the registration of medical devices in 2013, 2014, 2015

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • cosmetics-gmp

    Cosmetics GMP Good Manufacturing Practices now in force in China

    Cosmetics GMP in China came into force on July ...
  • china-vaccine-production

    China vaccine production and distribution rules released

    China Vaccine Production and Distribution Rules...
  • Technical Guidelines Essential Principles

    Technical Guidelines for Essential Principles of Safety and Performance of Medical Devices

    Technical Guidelines for Essential Principles o...
  • China drug real-world study design

    China drug real-world study design and protocol framework guidelines is open for comments

    China drug real-world study design and protocol...
  • contract manufacturing of Hong Kong medical device and drug in GBA

    Contract manufacturing of Hong Kong medical device and drug in GBA supported by China NMPA

    Contract manufacturing of Hong Kong medical dev...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.